Expression of Annexin A1 in paclitaxel-resistant ovarian carcinoma and its clinical significance.
10.3969/j.issn.1672-7347.2014.08.005
- Author:
Lingzhi ZOU
1
;
Lanqin CAO
;
Hong YI
Author Information
1. Department of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha 410008, China).
- Publication Type:Journal Article
- MeSH:
Annexin A1;
metabolism;
Blotting, Western;
Down-Regulation;
Drug Resistance, Neoplasm;
Female;
Humans;
Ovarian Neoplasms;
drug therapy;
metabolism;
Paclitaxel;
pharmacology
- From:
Journal of Central South University(Medical Sciences)
2014;39(8):784-789
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the correlation of Annexin A1 (ANXA1) expression with paclitaxel response and clinicopathological features of ovarian carcinoma.
METHODS:The expression levels of ANXA1 in ovarian carcinoma SKOV3/Taxol-25 and SKOV3 cell lines were detected by Western blot and real time-PCR. The expression of ANXA1 protein in 42 specimens of ovarian carcinoma was examined by immunhistochemistry. The correlation of ANXA1 expression with paclitaxel response and clinicopathological features of ovarian carcinoma was analyzed.
RESULTS:The expression level of ANXA1 was significantly lower in SKOV3/Taxol-25 cell line than that in SKOV3 cell line (P<0.05). The positive specimens of ANXA1 expression in paclitaxel-resistant tissues (14/20) were significantly lower than those in the sensitive ones (21/22, P<0.05), and there was also a significant difference between the mild and the strong positive specimens (P<0.01). The expression of ANXA1 protein showed no correlation with the type of mophology and histological grade of ovarian cancer (P>0.05), but it was correlated with the clinical stage(P<0.05).
CONCLUSION:ANXA1 expression is downregulated in paclitaxel-resistant ovarian carcinoma, which might be a valuable predictor for paclitaxel susceptibility of ovarian carcinoma.
